Studies have demonstrated that individuals carrying specific genes exhibit significantly elevated risks of developing NDDs: for instance, the APP gene carried by patients with AD [16], and the α-synuclein (SNCA) gene carried by patients with Parkinson’s diseases (PD) [17]. This evidence concerns the gene SNCA and Alzheimer disease.